Bengaluru-based biotech startup Immuneel Therapeutics has signed an MoU with Tata Memorial Centre (TMC). Under the MoU, the two organisations will collaborate on a broad range of initiatives in cell and gene therapy, including clinical studies, translational research, manufacturing expansion, policy engagement and educational programmes.Among the first projects identified under the partnership is a Phase 2 extension study evaluating the safety and efficacy of IMN-003A cell therapy in adult and paediatric patients with relapsed or refractory CD19-positive B-cell malignancies. The collaboration will also explore a Phase 1/2 clinical study of IMN-006 cell therapy in patients with relapsed or refractory multiple myeloma.Dr Navin Khattry, Deputy Director, Clinical Services, ACTREC, said, “Our partnership with Immuneel reflects a shared commitment to accelerating cutting-edge cell and gene therapy research while ensuring that transformative cancer treatments become more accessible to patients in India.”Amit Mookim, Board Director and CEO of Immuneel Therapeutics, said, “This collaboration with Tata Memorial Centre is an important milestone in Immuneel’s mission to advance patient-centric cell and gene therapies from India for the world. Together, we aim to build a strong foundation for next-generation cancer care and contribute to the long-term growth of India’s advanced therapeutics landscape.”Beyond clinical trials, the collaboration will focus on basic and preclinical research on pipeline products, co-development of novel therapeutic candidates, and initiatives to expand manufacturing capabilities for advanced therapies in India. The partners also plan to conduct educational and knowledge-sharing programmes to build awareness and strengthen expertise in the rapidly evolving field of cell and gene therapy.Published on July 15, 2026